Breast Cancer

Updates of Key Studies Differ on Relative Benefit of Nab-Paclitaxel in Breast Cancer

Two important studies, both updates of earlier findings and presented at the 2017 San Antonio Breast Cancer Symposium, provided different findings as to...

Bladder Cancer

Avelumab in Advanced Urothelial Carcinoma: Further Study Needed to Clarify its Role

As reviewed in this issue of The ASCO Post, Patel and colleagues have presented data from the phase I JAVELIN study evaluating avelumab in platinum-refractory...

Breast Cancer

ASCO/CCO Focused Guideline Update on Role of Bone-Modifying Agents in Metastatic Breast Cancer

As reported by Catherine Van Poznak, MD, FASCO, of the University of Michigan, Ann Arbor, and colleagues in the Journal of Clinical Oncology, ASCO and Cancer Care Ontario...


Advertisement

More Top Stories

Kidney Cancer

Daniel J. George, MD, on RCC: Study Results on Adjuvant Treatment

Hematologic Malignancies

Daratumumab Shows Efficacy in Amyloid Light-Chain Amyloidosis

DARATUMUMAB (DARZALEX) may be an effective treatment for systemic amyloid light-chain (AL) amyloidosis, according to phase II studies reported at the 2017 American Society of Hematology (ASH) Annual Meeting & Exposition.1,2 While the cohorts were small and the arms uncontrolled, the findings...

Advertisement

Family History Increases Breast Cancer Risk, Even in Women Aged 65 and Older

A family history of breast cancer continues to significantly increase chances of developing invasive breast tumors in women aged 65 years and older, according to research published by Braithwaite et al in JAMA Internal Medicine. The findings could impact mammography screening decisions later in...

Kidney Cancer

Sumanta K. Pal, MD, on Renal Cancer Immunotherapy: Latest Developments

Solid Tumors
Breast Cancer

I’m Not a Victim of Cancer

What I thought after feeling a large, hard lump—similar to the feel of a granola bar—in my left breast was that I probably pulled a muscle while playing with my two young children, ages 7 and 5. Cancer never entered my mind until I asked my husband to feel the lump, and he immediately said, with...

Genomics/Genetics
Issues in Oncology

Making Personalized Medicine a Reality for More Patients With Cancer

  This past September, Olivier Elemento, PhD, Associate Director of the Institute for Computational Biomedicine and Director of the Laboratory of Cancer Systems Biology at Weill Cornell Medicine in New York, was named Director of Weill Cornell’s Englander Institute for Precision Medicine. In this...

Association of MHC Class II and PD-L1 Expression With Outcome in Classical Hodgkin Lymphoma

As reported in the Journal of Clinical Oncology, Roemer et al found that programmed death cell ligand 1 (PD-L1) expression and major histocompatibility complex (MHC) class II positivity on Hodgkin Reed-Sternberg (HRS) cells may predict favorable outcome with programmed cell death protein 1 (PD-1)...

Bladder Cancer

Joaquim Bellmunt, MD, PhD, on Bladder Cancer: The Future of Immunotherapies

Solid Tumors

Individualized Adaptive Stereotactic Body Radiotherapy for Primary and Metastatic Liver Tumors

In a single-center phase II study reported in JAMA Oncology, Feng and colleagues found that individualized adaptive stereotactic body radiotherapy achieved high rates of local tumor control with low complication rates in patients with liver tumors and preexisting liver dysfunction. Theodore S....

Advertisement

FDA’s Oncologic Drugs Advisory Committee to Review Potential New Use of Blinatumomab

On February 14, Amgen announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the supplemental biologics license application (sBLA) for blinatumomab (Blincyto) for the treatment of patients with minimal residual disease...